Antitumoral actions of the antiobesity drug orlistat Xenical

Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA 3 -mediated transcriptional repression of Her 2/neu (erb. B-2) oncogene J. A. Menendez, L. Vellon, R. Lupu Annals of Oncology Volume 16 Issue 8 Pages 1253 -1267 (August 2005) DOI: 10. 1093/annonc/mdi 239 Copyright © 2005 European Society for Medical Oncology Terms and Conditions

Figure 1 Annals of Oncology 2005 161253 -1267 DOI: (10. 1093/annonc/mdi 239) Copyright © 2005 European Society for Medical Oncology Terms and Conditions

Figure 2 Annals of Oncology 2005 161253 -1267 DOI: (10. 1093/annonc/mdi 239) Copyright © 2005 European Society for Medical Oncology Terms and Conditions

Figure 3 Annals of Oncology 2005 161253 -1267 DOI: (10. 1093/annonc/mdi 239) Copyright © 2005 European Society for Medical Oncology Terms and Conditions

Figure 4 Annals of Oncology 2005 161253 -1267 DOI: (10. 1093/annonc/mdi 239) Copyright © 2005 European Society for Medical Oncology Terms and Conditions

Figure 5 Annals of Oncology 2005 161253 -1267 DOI: (10. 1093/annonc/mdi 239) Copyright © 2005 European Society for Medical Oncology Terms and Conditions